A COVID-19 vaccine produced in a partnership between Sanofi and GlaxoSmithKline showed strong results in a new trial, the companies announced on Monday. Interim results from a phase two trial showed development of antibodies against the CCP (Chinese Communist Party) virus in 95 to 100 percent of volunteers, who ranged in age from 18 to 95. “With these…